| UPDATE 2-FDA delays Endo's testosterone gel approval |
| S&P Equity Research analyst Steven Silver viewed the regulatory setback as modest, given Endo's minimal $10 million upfront payment to license drug's U.S. rights. Silver reiterated his "hold" r... |
More
-
How FirstInland IPO hit N100bn returns
Like the offers of many other banks that came into the stock market before it for capital sourcing, the just concluded Initial Public Offer of FirstInland Bank appears to have been over- subscribed. Facts from the Issuing Houses revealed this to us
-
UPDATE 2-India's SBI $4.1 bln rights issue covered -sources
Shares in SBI closed down 2.5 percent at 1,592.20 rupees, down 31 percent since the issue opened on Feb. 18, having fallen to a five-month low of 1,582.25 rupees in the afternoon.